Table 1 Patient Characteristics
FOLFOX-4 (n = 29) | Topotecan (n = 26) | P | |
|---|---|---|---|
N (%) | N (%) | ||
Median age, years (range) | 60 (33–85) | 66 (51–80) | 0.032 |
Histology | |||
Serous | 22 (75.9) | 22 (84.6) | |
Non-serous | 7 (24.1) | 4 (15.4) | 0.422 |
FIGO stage at presentation | |||
I-II | 3 (14.3) | 2 (12.5) | |
III | 16 (76.2) | 11 (68.7) | |
IV | 2 (9.5) | 3 (18.8) | 0.529 |
Unknown/missing | 8 | 10 | |
Grade | |||
I | 5 (20.8) | 7 (29.2) | |
II | 5 (20.8) | 4 (16.7) | |
III | 14 (58.4) | 13 (54.1) | 0.612 |
Unknown/missing | 5 | 2 | |
ECOG Perfomance status | |||
0–1 | 27 (93.1) | 25 (96.1) | |
2 | 2 (6.9) | 1 (3.9) | 0.622 |
Sites of metastasis | |||
Only abdominal | 11 (37.9) | 20 (76.9) | |
Abdominal + extra-abdominal | 18 (62.1) | 6 (23.1) | 0.004 |
Number of involved sites | |||
1 | 4 (13.8) | 5 (19.2) | |
2 | 10 (34.5) | 10 (38.5) | |
≥ 3 | 15 (51.7) | 11 (42.3) | 0.459 |
Median interval from initial diagnosis, months (range) | 47 (11.5–248) | 40.4 (9.7–1301) | 0.129 |
Lines of previous treatments | |||
≤ 4 | 15 (51.7) | 20 (76.9) | |
> 4 | 14 (48.3) | 6 (23.1) | 0.055 |
Number of treatment cycles | |||
Median value (range) | 4 (1–17) | 3 (1–8) | 0.038 |
Baseline NLR | |||
< 3 | 13 (46.4) | 20 (80.0) | |
≥ 3 | 15 (53.6) | 5 (20.0) | 0.013 |
Unknown/missing | 1 | 1 | |
Baseline PLR | |||
< 210 | 13 (46.4) | 18 (72.0) | |
≥ 210 | 15 (53.6) | 7 (28.0) | 0.062 |
Unknown/missing | 1 | 1 | |
Median baseline Hb, g/dL (range) | 11.1 (8.3–15.0) | 12.1 (8.9–14.3) | 0.058 |
Median baseline Ca125, ng/mL (range) | 289.9 (13.3–11,344.0) | 100.2 (12.6–10,805.0) | 0.259 |
Median baseline BMI, kg/m2 (range) | 23.88 (15.24–32.04) | 23.16 (19.53–30.30) | 0.345 |